{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T08:06:24Z","timestamp":1791446784768,"version":"4.3.3"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.ahj.2018.03.008","type":"journal-article","created":{"date-parts":[[2018,3,18]],"date-time":"2018-03-18T18:28:57Z","timestamp":1521397737000},"page":"44-50","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":100,"special_numbering":"C","title":["Oral anti-Xa anticoagulation after trans-aortic valve implantation for aortic stenosis: The randomized ATLANTIS trial"],"prefix":"10.1016","volume":"200","author":[{"given":"Jean-Philippe","family":"Collet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Berti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angel","family":"Cequier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Van Belle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Lefevre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Leprince","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz-Josef","family":"Neumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Vicaut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Montalescot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.ahj.2018.03.008_bb0005","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa1008232","article-title":"Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery","volume":"363","author":"Leon","year":"2010","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.ahj.2018.03.008_bb0010","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1056\/NEJMoa1400590","article-title":"Transcatheter aortic-valve replacement with a self-expanding prosthesis","volume":"370","author":"Adams","year":"2014","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.ahj.2018.03.008_bb0015","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1056\/NEJMoa1700456","article-title":"Surgical or transcatheter aortic-valve replacement in intermediate-risk patients","volume":"376","author":"Reardon","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2018.03.008_bb0020","first-page":"354","article-title":"Transcatheter or surgical aortic valve replacement for patients with severe, symptomatic, aortic stenosis at low to intermediate surgical risk: a clinical practice guideline","volume":"i5085","author":"Vandvik","year":"2016","journal-title":"BMJ"},{"issue":"25","key":"10.1016\/j.ahj.2018.03.008_bb0025","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1161\/CIRCULATIONAHA.112.110981","article-title":"Timing, predictive factors, and prognostic value of cerebrovascular events in a large cohort of patients undergoing transcatheter aortic valve implantation","volume":"126","author":"Nombela-Franco","year":"2012","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.ahj.2018.03.008_bb0030","doi-asserted-by":"crossref","first-page":"62","DOI":"10.4244\/EIJV8I1A11","article-title":"Cerebrovascular accidents complicating transcatheter aortic valve implantation: frequency, timing and impact on outcomes","volume":"8","author":"Stortecky","year":"2012","journal-title":"EuroIntervention"},{"issue":"21","key":"10.1016\/j.ahj.2018.03.008_bb0035","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1056\/NEJMoa1509233","article-title":"Possible subclinical leaflet thrombosis in bioprosthetic aortic valves","volume":"373","author":"Makkar","year":"2015","journal-title":"N Engl J Med"},{"issue":"28","key":"10.1016\/j.ahj.2018.03.008_bb0040","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1093\/eurheartj\/ehx369","article-title":"Natural history of subclinical leaflet thrombosis affecting motion in bioprosthetic aortic valves","volume":"38","author":"Sondergaard","year":"2017","journal-title":"Eur Heart J"},{"issue":"45","key":"10.1016\/j.ahj.2018.03.008_bb0045","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1093\/eurheartj\/ehu298","volume":"35","author":"Members","year":"2014","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.ahj.2018.03.008_bb0050","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1016\/j.jtcvs.2012.03.001","volume":"144","author":"Holmes","year":"2012","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"25","key":"10.1016\/j.ahj.2018.03.008_bb0055","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1016\/j.jacc.2013.03.029","article-title":"Antithrombotic treatment in transcatheter aortic valve implantation: insights for cerebrovascular and bleeding events","volume":"62","author":"Rod\u00e9s-Cabau","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.ahj.2018.03.008_bb0060","first-page":"520","article-title":"Transcatheter aortic valve implantation: a Canadian Cardiovascular Society position statement","volume":"28","author":"Webb","year":"2012","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.ahj.2018.03.008_bb0065","first-page":"10","article-title":"2017 AHA\/ACC Focused Update of the 2014 AHA\/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","author":"Nishimura","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.ahj.2018.03.008_bb0070","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1016\/j.amjcard.2011.07.049","article-title":"Dual antiplatelet therapy versus aspirin alone in patients undergoing transcatheter aortic valve implantation","volume":"108","author":"Ussia","year":"2011","journal-title":"Am J Cardiol"},{"issue":"13","key":"10.1016\/j.ahj.2018.03.008_bb0075","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/j.jcin.2017.04.014","volume":"10","author":"Rod\u00e9s-Cabau","year":"2017","journal-title":"JACC Cardiovasc Interv"},{"issue":"9872","key":"10.1016\/j.ahj.2018.03.008_bb0080","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","article-title":"Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial","volume":"381","author":"Dewilde","year":"2013","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.ahj.2018.03.008_bb0085","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1093\/eurheartj\/ehq330","article-title":"ISAR-REACT 3A: a study of reduced dose of unfractionated heparin in biomarker negative patients undergoing percutaneous coronary intervention","volume":"31","author":"Schulz","year":"2010","journal-title":"Eur Heart J"},{"issue":"25","key":"10.1016\/j.ahj.2018.03.008_bb0090","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of bleeding in patients with atrial fibrillation undergoing PCI","volume":"375","author":"Gibson","year":"2016","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.ahj.2018.03.008_bb0095","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","article-title":"Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation","volume":"377","author":"Cannon","year":"2017","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.ahj.2018.03.008_bb0100","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1016\/j.jcin.2016.06.025","article-title":"Warfarin and antiplatelet therapy versus warfarin alone for treating patients with atrial fibrillation undergoing transcatheter aortic valve replacement","volume":"9","author":"Abdul-Jawad Altisent","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"issue":"21","key":"10.1016\/j.ahj.2018.03.008_bb0105","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1093\/eurheartj\/ehs253","article-title":"2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation * Developed with the special contribution of the European Heart Rhythm Association","volume":"33","author":"Camm","year":"2012","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.ahj.2018.03.008_bb0110","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.amjcard.2012.03.049","article-title":"Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation","volume":"110","author":"Miller","year":"2012","journal-title":"Am J Cardiol"},{"issue":"11","key":"10.1016\/j.ahj.2018.03.008_bb0115","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ahj.2018.03.008_bb0120","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","article-title":"Apixaban in patients with atrial fibrillation","volume":"364","author":"Connolly","year":"2011","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.ahj.2018.03.008_bb0125","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.jacc.2012.09.001","article-title":"Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document","volume":"60","author":"Kappetein","year":"2012","journal-title":"J Am Coll Cardiol"},{"issue":"36","key":"10.1016\/j.ahj.2018.03.008_bb0130","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1093\/eurheartj\/ehx391","article-title":"2017 ESC\/EACTS Guidelines for the management of valvular heart disease","volume":"38","author":"Baumgartner","year":"2017","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.ahj.2018.03.008_bb0135","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur Heart J"},{"issue":"38","key":"10.1016\/j.ahj.2018.03.008_bb0140","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.ahj.2018.03.008_bb0145","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/ALN.0000000000001631","article-title":"Management of severe bleeding in patients treated with direct oral anticoagulants: an observational registry analysis","volume":"127","author":"Albaladejo","year":"2017","journal-title":"Anesthesiology"},{"issue":"19","key":"10.1016\/j.ahj.2018.03.008_bb0150","first-page":"1455","article-title":"Management of antithrombotic therapy after bleeding in patients with coronary artery disease and\/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis","volume":"38","author":"Halvorsen","year":"2016","journal-title":"Eur Heart J"},{"issue":"11","key":"10.1016\/j.ahj.2018.03.008_bb0155","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1056\/NEJMoa064247","article-title":"Idraparinux versus standard therapy for venous thromboembolic disease","volume":"357","author":"van Gogh Investigators","year":"2007","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ahj.2018.03.008_bb0160","first-page":"408","volume":"52","author":"Capodanno","year":"2017","journal-title":"Eur J Cardiol"},{"issue":"23","key":"10.1016\/j.ahj.2018.03.008_bb0165","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report from the Bleeding Academic Research Consortium (BARC)","volume":"123","author":"Mehran","year":"2011","journal-title":"Circulation"},{"issue":"20","key":"10.1016\/j.ahj.2018.03.008_bb0170","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1001\/jama.2012.54506","article-title":"Association of warfarin therapy duration after bioprosthetic aortic valve replacement with risk of mortality, thromboembolic complications, and bleeding","volume":"308","author":"M\u00e9rie","year":"2012","journal-title":"JAMA J Am Med Assoc"},{"issue":"10","key":"10.1016\/j.ahj.2018.03.008_bb0175","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.amjcard.2012.01.364","article-title":"Comparison of complications and outcomes to one year of transcatheter aortic valve implantation versus surgical aortic valve replacement in patients with severe aortic stenosis","volume":"109","author":"Tamburino","year":"2012","journal-title":"Am J Cardiol"},{"issue":"3","key":"10.1016\/j.ahj.2018.03.008_bb0180","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1161\/CIRCULATIONAHA.110.946533","article-title":"Incidence and predictors of early and late mortality after transcatheter aortic valve implantation in 663 patients with severe aortic stenosis","volume":"123","author":"Tamburino","year":"2011","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.ahj.2018.03.008_bb0185","doi-asserted-by":"crossref","first-page":"129","DOI":"10.4244\/EIJV8I1A20","article-title":"Risk of stroke after transcatheter aortic valve implantation (TAVI): a meta-analysis of 10,037 published patients","volume":"8","author":"Eggebrecht","year":"2012","journal-title":"EuroIntervention"},{"issue":"1","key":"10.1016\/j.ahj.2018.03.008_bb0190","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jcin.2016.10.023","article-title":"Apixaban in patients with atrial fibrillation after transfemoral aortic valve replacement","volume":"10","author":"Seeger","year":"2017","journal-title":"JACC Cardiovasc Interv"},{"issue":"10087","key":"10.1016\/j.ahj.2018.03.008_bb0195","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1016\/S0140-6736(17)30757-2","article-title":"Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study","volume":"389","author":"Chakravarty","year":"2017","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.ahj.2018.03.008_bb0200","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ahj.2015.11.008","article-title":"Rationale and design of POPular-TAVI: antiPlatelet therapy fOr Patients undergoing Transcatheter Aortic Valve Implantation","volume":"173","author":"Nijenhuis","year":"2016","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2018.03.008_bb0205","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ahj.2016.10.017","article-title":"Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study","volume":"184","author":"Windecker","year":"2017","journal-title":"Am Heart J"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870318300802?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870318300802?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T06:00:05Z","timestamp":1757570405000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870318300802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":41,"alternative-id":["S0002870318300802"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2018.03.008","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral anti-Xa anticoagulation after trans-aortic valve implantation for aortic stenosis: The randomized ATLANTIS trial","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2018.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}